Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 7/20 | 0.67 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.67 |
| ▸ | PPARA | Q07869 | 3/20 | 0.65 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.61 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.58 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.58 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | MGLL | Q99685 | 1/20 | 0.57 |
| ▸ | ALB | P02768 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1799635 | 1.00 | FFAR1 (0.67) | FFAR1FFAR4PPARAALOX5NR4A1 | |
| SCHEMBL1171526 | 1.00 | FFAR1 (0.67) | FFAR1FFAR4PPARAALOX5NR4A1 | |
| SCHEMBL1115038 | 0.98 | FFAR1 (0.69) | FFAR1FFAR4PPARAALOX5NR4A1 | |
| SCHEMBL1172055 | 0.93 | FFAR1 (0.71) | FFAR1FFAR4PPARAALOX5NR4A1 | |
| SCHEMBL1171635 | 0.89 | NR4A2 (0.61) | FFAR1FFAR4NR4A2 | |
| SCHEMBL20834076 | 0.88 | FFAR1 (0.77) | FFAR1FFAR4ALOX5MGLL | |
| SCHEMBL8889196 | 0.88 | FFAR1 (0.77) | FFAR1FFAR4ALOX5MGLL | |
| SCHEMBL1171970 | 0.88 | NR4A2 (0.63) | FFAR1FFAR4NR4A2 | |
| SCHEMBL8922076 | 0.86 | NR4A2 (0.61) | FFAR1FFAR4PPARAALOX5NR4A2 | |
| SCHEMBL25228768 | 0.86 | PPARA (0.72) | FFAR1FFAR4PPARAALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9102622-B2 | Fatty acid amide hydrolase inhibitors | UNIVERSITY OF CONNECTICUT (US) | 2015-08-11 | — | — | US | disclosed |
| US-20110071178-A1 | Methods and Compounds for Modulating Cannabinoid Activity | NORTHEASTERN UNIVERSITY (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110039874-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS FOR MODULATION OF CANNABINOID ACTIVITY | NORTHEASTERN UNIVERSITY (US) | 2011-02-17 | — | — | US | disclosed |
| US-20100234379-A1 | Dual modulation of endocannabinoid transport and fatty-acid amide hydrolase for treatment of excitotoxicity | CONNECTICUT, UNIVERSITY OF | 2010-09-16 | — | — | US | disclosed |
| EP-2203058-A1 | METHODS AND COMPOUNDS FOR MODULATING CANNABINOID ACTIVITY | NORTHEASTERN UNIVERSITY (US) | 2010-07-07 | — | — | EP | disclosed |
| EP-2203412-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS FOR MODULATION OF CANNABINOID ACTIVITY | NORTHEASTERN UNIVERSITY (US) | 2010-07-07 | — | — | EP | disclosed |
| US-20090306016-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | UNIVERSITY OF CONNECTICUT | 2009-12-10 | — | — | US | disclosed |
| EP-2051964-A2 | FATTY ACID AMIDE HYDROLASE INHIBITORS | University of Connecticut (US) | 2009-04-29 | — | — | EP | disclosed |
| WO-2009052320-A1 | METHODS AND COMPOUNDS FOR MODULATING CANNABINOID ACTIVITY | NORTHEASTERN UNIVERSITY (US) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009052319-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS FOR MODULATION OF CANNABINOID ACTIVITY | NORTHEASTERN UNIVERSITY (US) | 2009-04-23 | — | — | WO | disclosed |
| WO-2008013963-A2 | FATTY ACID AMIDE HYDROLASE INHIBITORS | UNIVERSITY OF CONNECTICUT (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039874-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS FOR MODULATION OF CANNABINOID ACTIVITY | MGLL, FAAH, FAAH2 | FFAR1 96/4885FFAR4 116/4885PPARA 186/4885 |
| US-20090306016-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | FAAH, FAAH2, CNR2 | FFAR1 16/4885FFAR4 17/4885PPARA 254/4885 |
| US-20100234379-A1 | Dual modulation of endocannabinoid transport and fatty-acid amide hydrolase for treatment of excitotoxicity | FAAH, FAAH2, CNR2 | FFAR1 27/4885FFAR4 41/4885PPARA 613/4885 |
| US-20110071178-A1 | Methods and Compounds for Modulating Cannabinoid Activity | FAAH, FAAH2, CNR2 | FFAR1 110/4885FFAR4 114/4885PPARA 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.